Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. raised its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 17.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 256,927 shares of the medical research company's stock after purchasing an additional 39,042 shares during the period. Mawer Investment Management Ltd. owned about 0.92% of Bio-Rad Laboratories worth $84,403,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BIO. Venturi Wealth Management LLC grew its stake in Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after acquiring an additional 87 shares during the last quarter. Picton Mahoney Asset Management grew its position in shares of Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc acquired a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $33,000. UMB Bank n.a. increased its stake in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares in the last quarter. Finally, Cape Investment Advisory Inc. acquired a new position in shares of Bio-Rad Laboratories during the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on BIO. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Royal Bank of Canada reiterated an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and an average target price of $395.20.

Remove Ads

Bio-Rad Laboratories Trading Down 3.4 %

NYSE BIO traded down $8.33 during trading hours on Thursday, hitting $237.19. 130,144 shares of the company's stock were exchanged, compared to its average volume of 289,593. The business's 50 day moving average is $286.97 and its 200-day moving average is $320.81. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. Bio-Rad Laboratories, Inc. has a 12-month low of $233.47 and a 12-month high of $387.99. The firm has a market capitalization of $6.64 billion, a P/E ratio of -3.65 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.